Financial News
Articles published by Ocugen
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
October 22, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
October 10, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
October 09, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
October 02, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
September 05, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
August 05, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
May 10, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024
From Ocugen
Via GlobeNewswire
Tickers
OCGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.